Johnson & Johnson COVID-19 Vaccine

Kathryn Dzintars, Pharm.D., BCPS
Johnson & Johnson COVID-19 Vaccine is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

VACCINE TYPE

  • The Janssen COVID-19 vaccine is a suspension consisting of a replication-incompetent recombinant adenovirus type 26 (Ad26) vector expressing the SARS-CoV-2 spike (S) protein in a stabilized conformation.
    • Single intramuscular (IM) dose to be given to patients 18 years of age and older.
  • The U.S. FDA issued an Emergency Use Authorization (EUA) to permit the emergency use of the Janssen COVID-19 vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older.
    • On May 5, 2022, the FDA revised the criteria for the EUA limiting the vaccine’s use due to the perceived risk of thrombosis with thrombocytopenia syndrome (TTS) within 1 - 2 weeks after receipt of the vaccine.
      • Use of the Janssen COVID-19 vaccine is limited to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.
    • Mandatory requirements for the administration of the Janssen vaccine under the EUA are as follows:
      • The vaccine is authorized in patients ≥ 18 years of age.
      • The vaccination provider must give the individual receiving the Janssen vaccine or their caregiver the “Fact Sheet for Recipients and Caregivers” prior to the individual receiving the Janssen vaccine.
      • Vaccine providers must include vaccine information to either the state’s or local jurisdiction’s Immunization Information System or other designated systems.
      • Vaccine providers are responsible for reporting certain events to the Vaccine Adverse Events Reporting System (VAERS):
        • Vaccine administration errors whether or not associated with an adverse event
        • Serious adverse events include death, life-threatening adverse events, inpatient hospitalization/prolonged hospitalization, persistent or significant incapacity, congenital anomaly/birth defects
        • Cases of the multisystem inflammatory syndrome (MIS) in children and adults
        • Cases of COVID-19 that result in hospitalization and death
      • Vaccine providers are responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Janssen vaccine.
    • The CDC recommended that anyone 18 years of age or older be given a booster shot at least 2 months after the initial dose.
      • Booster doses should be provided with one of the mRNA vaccines (Pfizer BioNTech or Moderna)
      • On March 29, 2022, the CDC recommended that a second booster dose with an available mRNA vaccine be provided 4 months after the initial booster.

-- To view the remaining sections of this topic, please or --

VACCINE TYPE

  • The Janssen COVID-19 vaccine is a suspension consisting of a replication-incompetent recombinant adenovirus type 26 (Ad26) vector expressing the SARS-CoV-2 spike (S) protein in a stabilized conformation.
    • Single intramuscular (IM) dose to be given to patients 18 years of age and older.
  • The U.S. FDA issued an Emergency Use Authorization (EUA) to permit the emergency use of the Janssen COVID-19 vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older.
    • On May 5, 2022, the FDA revised the criteria for the EUA limiting the vaccine’s use due to the perceived risk of thrombosis with thrombocytopenia syndrome (TTS) within 1 - 2 weeks after receipt of the vaccine.
      • Use of the Janssen COVID-19 vaccine is limited to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.
    • Mandatory requirements for the administration of the Janssen vaccine under the EUA are as follows:
      • The vaccine is authorized in patients ≥ 18 years of age.
      • The vaccination provider must give the individual receiving the Janssen vaccine or their caregiver the “Fact Sheet for Recipients and Caregivers” prior to the individual receiving the Janssen vaccine.
      • Vaccine providers must include vaccine information to either the state’s or local jurisdiction’s Immunization Information System or other designated systems.
      • Vaccine providers are responsible for reporting certain events to the Vaccine Adverse Events Reporting System (VAERS):
        • Vaccine administration errors whether or not associated with an adverse event
        • Serious adverse events include death, life-threatening adverse events, inpatient hospitalization/prolonged hospitalization, persistent or significant incapacity, congenital anomaly/birth defects
        • Cases of the multisystem inflammatory syndrome (MIS) in children and adults
        • Cases of COVID-19 that result in hospitalization and death
      • Vaccine providers are responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Janssen vaccine.
    • The CDC recommended that anyone 18 years of age or older be given a booster shot at least 2 months after the initial dose.
      • Booster doses should be provided with one of the mRNA vaccines (Pfizer BioNTech or Moderna)
      • On March 29, 2022, the CDC recommended that a second booster dose with an available mRNA vaccine be provided 4 months after the initial booster.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: May 18, 2022